Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2585617rdf:typepubmed:Citationlld:pubmed
pubmed-article:2585617lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0026845lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0007138lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0699885lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0205281lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0231174lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:2585617lifeskim:mentionsumls-concept:C0439807lld:lifeskim
pubmed-article:2585617pubmed:issue6lld:pubmed
pubmed-article:2585617pubmed:dateCreated1989-12-28lld:pubmed
pubmed-article:2585617pubmed:abstractTextPatients with muscle invasive carcinoma of the bladder treated with radical radiation were prospectively documented and followed in an attempt to identify prognostic factors predictive of the response to treatment. Data on 121 consecutive patients treated with radical radiation between 1981 and 1985 are presented. Over-all actuarial survival of the patient population (median age 70 years) was 31.6% at 5 years and cause-specific survival was 44.8%. At analysis 33 of 121 patients (27.3%) were alive with preserved bladder function. Independent prognostic factors for cause-specific survival and for complete response with radical radiation were tumor configuration, hemoglobin level and clinical stage. The rate free of local relapse was significantly influenced by stage and presence of coexistent carcinoma in situ. The study suggests that factors other than stage and grade influence prognosis in invasive bladder cancer and should be considered in interpreting treatment results.lld:pubmed
pubmed-article:2585617pubmed:languageenglld:pubmed
pubmed-article:2585617pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2585617pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2585617pubmed:statusMEDLINElld:pubmed
pubmed-article:2585617pubmed:monthDeclld:pubmed
pubmed-article:2585617pubmed:issn0022-5347lld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:ThomasG MGMlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:HawkinsN VNVlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:DuncanWWlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:JewettM AMAlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:ConnollyJ GJGlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:GarrettP GPGlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:RawlingsG AGAlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:Gospodarowicz...lld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:ChuaTTlld:pubmed
pubmed-article:2585617pubmed:authorpubmed-author:HermanJ GJGlld:pubmed
pubmed-article:2585617pubmed:issnTypePrintlld:pubmed
pubmed-article:2585617pubmed:volume142lld:pubmed
pubmed-article:2585617pubmed:ownerNLMlld:pubmed
pubmed-article:2585617pubmed:authorsCompleteNlld:pubmed
pubmed-article:2585617pubmed:pagination1448-53; discussion 1453-4lld:pubmed
pubmed-article:2585617pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:meshHeadingpubmed-meshheading:2585617-...lld:pubmed
pubmed-article:2585617pubmed:year1989lld:pubmed
pubmed-article:2585617pubmed:articleTitleRadical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis.lld:pubmed
pubmed-article:2585617pubmed:affiliationDepartment of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.lld:pubmed
pubmed-article:2585617pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2585617lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2585617lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2585617lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2585617lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2585617lld:pubmed